FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 158 filers reported holding FATE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $0 | -100.0% | 2 | -100.0% | 0.00% | -100.0% |
| Q4 2023 | $222 | +35.4% | 59,302 | -23.2% | 0.01% | +42.9% |
| Q3 2023 | $164 | +811.1% | 77,199 | +1962.5% | 0.01% | +600.0% |
| Q2 2023 | $18 | -14.3% | 3,743 | -0.6% | 0.00% | 0.0% |
| Q1 2023 | $21 | -44.7% | 3,764 | -0.3% | 0.00% | -50.0% |
| Q4 2022 | $38 | -100.0% | 3,777 | -16.8% | 0.00% | -50.0% |
| Q3 2022 | $102,000 | -28.2% | 4,542 | -20.8% | 0.00% | 0.0% |
| Q2 2022 | $142,000 | -36.0% | 5,732 | +0.2% | 0.00% | -20.0% |
| Q1 2022 | $222,000 | -42.2% | 5,723 | -12.9% | 0.01% | -37.5% |
| Q4 2021 | $384,000 | -0.8% | 6,571 | +0.6% | 0.01% | -11.1% |
| Q3 2021 | $387,000 | -34.6% | 6,535 | -4.2% | 0.01% | -18.2% |
| Q2 2021 | $592,000 | – | 6,825 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |